Risk and outcome of non‐Hodgkin lymphoma among classical Hodgkin lymphoma survivors

BACKGROUND Survivors of classical Hodgkin lymphoma (cHL) are at an increased risk of developing secondary non‐Hodgkin lymphomas (sNHLs). To the authors' knowledge, the outcome of patients with sNHL compared with their de novo counterparts (dnNHL) is unknown. METHODS Data from 26,826 cases of HL...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Vol. 119; no. 18; pp. 3385 - 3392
Main Authors: Xavier, Ana C., Armeson, Kent E., Hill, Elizabeth G., Costa, Luciano J.
Format: Journal Article
Language:English
Published: Hoboken, NJ Wiley-Blackwell 15.09.2013
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
Biological and medical sciences
Child
Child, Preschool
classical Hodgkin lymphoma
cohort studies
Female
Hematologic and hematopoietic diseases
Hodgkin Disease - epidemiology
Hodgkin Disease - mortality
Humans
Incidence
Infant
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Lymphoma, Non-Hodgkin - epidemiology
Lymphoma, Non-Hodgkin - mortality
Male
Medical sciences
Middle Aged
Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
non‐Hodgkin lymphoma
prognosis
Risk Factors
second primary neoplasms
SEER Program
Survivors
Treatment Outcome
Tumors
United States - epidemiology
Young Adult
United States
Prognosis
Survivor
classical Hodgkin lymphoma
Hodgkin disease
Risk
Malignant hemopathy
non-Hodgkin lymphoma
Malignant tumor
Non Hodgkin lymphoma
second primary neoplasms
Cancerology
Second cancer
Lymphoproliferative syndrome
Cohort study
Risk factor
cohort studies
Evolution
Cancer
prognosis
ISSN:0008-543X, 1097-0142, 1097-0142
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BACKGROUND Survivors of classical Hodgkin lymphoma (cHL) are at an increased risk of developing secondary non‐Hodgkin lymphomas (sNHLs). To the authors' knowledge, the outcome of patients with sNHL compared with their de novo counterparts (dnNHL) is unknown. METHODS Data from 26,826 cases of HL from the Surveillance, Epidemiology, and End Results (SEER) program that were diagnosed between 1992 and 2009 were used to obtain the risk of further development of different subtypes of sNHL. The survival of patients with sNHL was compared with that of matched patients with dnNHL. RESULTS The estimated cumulative incidence of sNHL was 2.50% (95% confidence interval [95% CI], 2.10‐2.89) at 15 years from the diagnosis of cHL. The standardized incidence ratio was 10.5 (95% CI, 8.9‐12.4) for aggressive B‐cell NHL, 4.0 (95% CI, 3.1‐5.1) for indolent B‐cell NHL, and 14.6 (95% CI, 10.3‐20.1) for T‐cell NHL. Patients with indolent B‐cell sNHL had a worse overall survival compared with their dnNHL counterparts (hazards ratio [HR] of death, 2.7; 95% CI, 1.3‐5.7). Survival was not significantly different between patients with sNHL and those with dnNHL with regard to aggressive B‐cell NHL (HR, 1.3; 95% CI, 0.6‐2.7) or T‐cell NHL (HR, 0.8; 95% CI, 0.3‐1.8). CONCLUSIONS The risk of developing sNHL after cHL is substantial. Although patients with indolent B‐cell sNHL have inferior survival, patients with aggressive B‐cell sNHL and T‐cell sNHL have survival comparable to that of their de novo counterparts. Cancer 2013;119:3385–92. © 2013 American Cancer Society. Survivors of classical Hodgkin lymphoma are at 7.5‐fold higher risk of developing non‐Hodgkin lymphoma of various histologies than the general population, Survivors who develop T‐cell and aggressive B‐cell non‐Hodgkin lymphoma appear to have survival that is similar to that of their de novo counterparts.
Bibliography:Presented at the 54th Annual Meeting of the American Society of Hematology; December 8‐10, 2012; Atlanta, GA.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ISSN:0008-543X
1097-0142
1097-0142
DOI:10.1002/cncr.28194